Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

Энергетическая физиология мозга КОРЗИНА ПОИСК НАВИГАТОР ЖУРНАЛЫ КНИГИ
ПАТЕНТЫ ПОИСК АВТОРЫ ОРГАНИЗАЦИИ КЛЮЧЕВЫЕ СЛОВА РУБРИКАТОР …

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …

The key pathological hallmarks—extracellular plaques and intracellular neurofibrillary
tangles (NFT)—described by Alois Alzheimer in his seminal 1907 article are still central to …

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss
and personality changes, eventually leading to dementia. The pathological hallmarks of AD …

Alzheimer's disease is a neurodegenerative disease that accounts for most of the 50-million
dementia cases worldwide in 2018. A large amount of evidence supports the amyloid …

Mass spectrometry-based proteomics empowers deep profiling of proteome and protein
posttranslational modifications (PTMs) in Alzheimer's disease (AD). Here we review the …

Alzheimer's disease is a devastating neurodegenerative disorder with no cure. Countless
promising therapeutics have shown efficacy in rodent Alzheimer's disease models yet failed …